Postherpetic Neuralgia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Postherpetic Neuralgia Clinical Trials Market Report Overview
The Postherpetic Neuralgia Clinical Trial provides an overview of Postherpetic Neuralgia Clinical trials scenario. The report provides top line data relating to the clinical trials on Postherpetic Neuralgia. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
Postherpetic Neuralgia Clinical Trials Market Segmentation by Regions and Countries
The key regions in the postherpetic neuralgia clinical trials market are Europe, the Asia-Pacific, North America, the Middle East & Africa, and South & Central America. Of all the clinical trials conducted on postherpetic neuralgia, as of February 2023, more than 40% of the clinical trials were conducted in the Asia-Pacific.
In the country wise analysis, as of February 2023, China has the highest number of postherpetic neuralgia clinical trials, followed by the US, Japan, Germany, the UK, Canada, Australia, Russia, Czech Republic, and South Korea
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of postherpetic neuralgia to central nervous system clinical trials as of February 2023. Out of all the clinical trials conducted in the G7 countries, the majority were in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, China has the highest proportion of postherpetic neuralgia to central nervous system clinical trials as of February 2023. Out of all the clinical trials conducted in the E7 countries, the majority were in China.
Postherpetic Neuralgia Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the postherpetic neuralgia clinical trials market, download a free report sample
Postherpetic Neuralgia Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the postherpetic neuralgia clinical trials market are institution, company, and the government. Out of them, around 75% of trials have been sponsored by company, followed by institution.
Postherpetic Neuralgia Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the postherpetic neuralgia clinical trials market, download a free report sample
Postherpetic Neuralgia Clinical Trials Market - Competitive Landscape
The leading sponsors in the postherpetic neuralgia clinical trials market are Viatris Inc, Pfizer Inc, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, GSK plc, AbbVie Inc, Sorrento Therapeutics Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Grunenthal GmbH. Viatris Inc has conducted the highest number of postherpetic neuralgia clinical trials and is followed by Pfizer Inc and Daiichi Sankyo Co Ltd.
Postherpetic Neuralgia Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading players in the postherpetic neuralgia clinical trials market, download a free report sample
Postherpetic Neuralgia Clinical Trials Market Report Overview
Key Regions | Europe, Asia-Pacific, North America, Middle East & Africa, and South & Central America |
Key Countries | The US, Germany, China, Canada, the UK, France, Poland, India, Japan, and Spain |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Viatris Inc, Pfizer Inc, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, GSK plc, AbbVie Inc, Sorrento Therapeutics Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Grunenthal GmbH |
Segments Covered in the Report
Postherpetic Neuralgia Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
Postherpetic Neuralgia Clinical Trials Country Outlook (2023)
- The US
- Germany
- China
- Canada
- The UK
- France
- Poland
- India
- Japan
- Spain
Postherpetic Neuralgia Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end-point status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with reasons for unaccomplishment.
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Pfizer Inc
Daiichi Sankyo Co Ltd
Astellas Pharma Inc
GSK plc
AbbVie Inc
Sorrento Therapeutics Inc
Merck & Co Inc
Teva Pharmaceutical Industries Ltd
Grunenthal GmbH
Table of Contents
Table
Figures
Frequently asked questions
-
Which was the leading region in the postherpetic clinical trials market?
Asia-Pacific had the highest number clinical trials conducted on postherpetic neuralgia, as of February 2023.
-
Which was the leading country in the G7 postherpetic clinical trials market?
Japan has the highest proportion of postherpetic neuralgia to central nervous system clinical trials as of February 2023.
-
Which was the leading country in the E7 postherpetic clinical trials market?
China has the highest proportion of postherpetic neuralgia to central nervous system clinical trials as of February 2023.
-
What are the key sponsor types in the postherpetic clinical trials market?
The key sponsor types in the postherpetic clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the postherpetic clinical trials market?
The leading sponsors in the postherpetic clinical trials market are Viatris Inc, Pfizer Inc, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, GSK plc, AbbVie Inc, Sorrento Therapeutics Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Grunenthal GmbH.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.